Acta Diabetologica

, Volume 32, Issue 1, pp 13–16 | Cite as

Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7–36 amide] in the fasting state in healthy subjects

  • C. Qualmann
  • M. A. Nauck
  • J. J. Holst
  • C. Ørskov
  • W. Creutzfeldt


GLP-1 (7–36 amide) stimulates insulin and suppresses glucagon secretion in normal subjects and may, in pharmacological doses, normalize hyperglycaemia in type 2 diabetic patients. It is not known whether such pharmacological doses can actually lower blood glucose to hypoglycaemic levels. Therefore, in seven normal fasting subjects, GLP-1 (7–36 amide) was infused intravenously at 0.3, 0.9 and 2.7 pmol/kg per min for 30 min each. The plasma concentration of GLP-1 (7–36 amide) increased dose-dependently, but insulin secretion (insulin, C-peptide) was stimulated only marginally. Glucagon was slightly suppressed, and plasma glucose was reduced, but not into the hypoglycaemic range. In conclusion, when plasma glucose concentrations are in the normal fasting range, GLP-1 (7–36 amide) is not able to stimulate insulin secretion to a degree that causes hypoglycaemia. This should limit the risk of hypoglycaemic responses when GLP-1 (7–36 amide) is administered in pharmacological doses to reduce hyperglycaemia in type 2 diabetic patients.

Key words

Incretin hormones Glucagon-like peptide 1 (7–36 amide) Hypoglycaemia Enteroinsular axis Insulin secretion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McIntyre N, Holdsworth CD, Turner DS, Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 25:1317–1324, 1965Google Scholar
  2. 2.
    Creutzfeldt W, Nauck MA, Gut hormones and diabetes mellitus. Diabetes Metab Rev 8:149–177, 1992Google Scholar
  3. 3.
    Göke R, Fehmann HC, Göke B, Glucagon-like peptide-1 (7–36) amide is a new incretin/enterogastrone candidate. Eur J Clin Invest 21:135–144, 1991Google Scholar
  4. 4.
    Ørskov C, Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701–711, 1992Google Scholar
  5. 5.
    Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF, Insulinotropic action of glucagonlike peptide-1-(7–37) in diabetic and nondiabetic subjects. Diabetes Care 15:270–276, 1992Google Scholar
  6. 6.
    Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W, Preserved incretin activity of GLP-1 [7–36 amide] but not of synthetic human GIP in patients with Type 2-diabetes mellitus. J Clin Invest 91:301–307, 1993Google Scholar
  7. 7.
    Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7–36 amide) in Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741–744, 1993Google Scholar
  8. 8.
    Gutniak M, Ørskov C, Holst JJ, Åhrén B, Efendic S, Antidiabetogenic effect of glucagon-like peptide-1 (7–36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326:1316–1322, 1992Google Scholar
  9. 9.
    Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W, Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. J Clin Endocrinol Metab 69:654–662, 1989Google Scholar
  10. 10.
    Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912–917, 1993Google Scholar
  11. 11.
    Kreymann B, Ghatei MA, Williams G, Bloom SR, Glucagon-like peptide 1 7–36: a physiological incretin in man. Lancet II:1300–1304, 1987Google Scholar
  12. 12.
    Kreymann B, Ghatei MA, Schusdziarra V, Bloom SR, Classen M, Haben GIP und GLP-1 7–36 NH2 beim Menschen einen Inkretineffekt unter physiologischen Glucosekonzentrationen (abstract)? Akt Endokrinol Stoffwechsel 11:130, 1990Google Scholar
  13. 13.
    Fridolf T, Böttcher G, Sundler F, Åhrén B, GLP-1 and GLP-1 (7–36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6:208–215, 1991Google Scholar
  14. 14.
    Qualmann C, Nauck M, Holst JJ, Ørskov C, Creutzfeldt W, Negligible insulinotropic action of exogenous glucagon-like peptide 1 (7–36 amide) at basal plasma glucose concentrations in healthy volunteers (abstract). Diabetologia 35:A109, 1992Google Scholar
  15. 15.
    Ørskov C, Holst JJ, Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165–174, 1987Google Scholar
  16. 16.
    Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J, Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behaviour. J Clin Endocrinol Metab 51:520–528, 1980Google Scholar
  17. 17.
    Nauck MA, Siegel EG, Creutzfeldt W, Prolonged maximal stimulation of insulin secretion in healthy subjects does not provoke preferential release of proinsulin. Pancreas 6:645–652, 1991Google Scholar
  18. 18.
    Theodorsson-Norheim E, Friedman and Quade tests: basic computer program to perform nonparametric two-way analysis of variance and multiple comparisons on ranks of several related samples. Comp Biol Med. 17:85–99, 1987Google Scholar
  19. 19.
    Göke R, Wagner B, Fehmann HC, Göke B, Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7–36) amide on the rat pancreas. Res Exp Med 193:97–103, 1993Google Scholar
  20. 20.
    Hvidberg A, Nielsen MT, Ørskov C, Holst JJ, Effect of glucagon-like peptide-1 (proglucagon 78–107 amide) on hepatic glucose production in healthy man. Metabolism 43:104–108, 1994Google Scholar
  21. 21.
    Hansen BC, Jen KLC, Pek SB, Wolfe RA, Rapid oscillations in plasma insulin, glucagon, and glucose in obese and normal weight humans. J Clin Endocrinol Metab 54:785–792, 1982Google Scholar
  22. 22.
    Kanse SM, Kreymann B, Ghatei MA, Bloom SR, Identification and characterization of glucagon-like peptide-1 7–36 amide-binding sites in the rat brain and lung. FEBS Lett 241:209–212, 1988Google Scholar
  23. 23.
    Seifert H, Gallwitz B, Schmidt WE, Creutzfeldt W, Mapping of125I-GIP-1(7–36)-NH2 binding sites in rat brain (abstract). Digestion 46 (Suppl 1):104, 1990Google Scholar
  24. 24.
    Wettergren A, Scholdager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ, Truncated GLP-1 (proglucagon 87–107 amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665–673, 1993Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • C. Qualmann
    • 1
  • M. A. Nauck
    • 1
  • J. J. Holst
    • 2
  • C. Ørskov
    • 2
  • W. Creutzfeldt
    • 1
  1. 1.Division of Gastroenterology and Endocrinology, Department of MedicineGeorg-August-UniversityGöttingenGermany
  2. 2.Department of Medical Anatomy and Physiology, Panum InstituteUniversity of CopenhagenDenmark

Personalised recommendations